已收盘 05-08 16:00:00 美东时间
-23.350
-5.47%
今日重点评级关注:Citizens:维持BioCryst制药"跑赢大市"评级,目标价从25美元升至28美元;富国银行:维持曼恩凯德生物医疗"超配"评级,目标价从8美元升至10美元
05-08 12:05
Axon Enterprise周四股价大涨,此前这家执法科技制造商公布的一季度财报显示,国际市场对泰瑟枪和执法记录仪的需求激增,推动公司业绩超预期并上调全年...
05-08 03:27
U.S. stocks drifted near records Thursday as oil slipped on Iran-Hormuz peace hopes. Coinbase, Airbnb and CoreWeave on deck after the close.
05-08 00:44
Piper Sandler analyst James Fish maintains Axon Enterprise (NASDAQ:AXON) with a Overweight and lowers the price target from $690 to $674.
05-07 21:28
AppLovin's (APP) first-quarter results and outlook, which surpassed estimates, drew positive reactions from analysts. Shares of the advertising solutions provider dipped about 1% premarket on Thursday...
05-07 20:54
华盛资讯5月7日讯,Axon Enterprise公布2026财年Q1业绩,公司Q1营收8.07亿美元,同比增长33.7%,归母净利润1.69亿美元,同比增长92.4%。
05-07 18:17
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Axon业绩会实录,以下是Q1 2026财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - 总营收:8.07亿美元,同比增长34%,连续第九个季度实现30%以上的营收增长 - 软件和服务营收:3.55亿美元,同比增长35% - 连接设备营收:4.53亿美元,同比增长33% - AI产品营收:同比增长超过700%(基数较小) - 国际营收:同比增长超过100%,占总营收的20% **盈利能力:** - 调整后EBITDA利润率:25%(Q1) - 年度EBITDA利润率目标:25.5%(公司重申) **现金流:** - 预期全年自由现
05-07 12:30
华盛资讯5月7日讯,Axon Enterprise公布2026财年Q1业绩,公司Q1营收8.07亿美元,同比增长33.8%,归母净利润1.69亿美元,同比增长92.4%。
05-07 07:51
Fastly Inc (NASDAQ:FSLY) shares are tumbling in Wednesday's after-hours session on the heels of the company's first-quarter results.
05-07 05:14
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03